Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI571 (Imatinib) in CML Refractory/Intolerant to Interferon-Alpha
NCT00006053Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2000
- Primary completion
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Jun 2000; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00006053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006053.